Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (STOK) is a clinical-stage biotechnology leader pioneering RNA-based medicines to address the root causes of severe genetic diseases. This page serves as the definitive source for official updates on therapeutic advancements, financial developments, and strategic initiatives related to their TANGO platform technology.
Investors and researchers will find curated press releases covering clinical trial progress, regulatory milestones, and peer-reviewed research on antisense oligonucleotide therapies. The repository includes updates on STOK's pipeline targeting central nervous system disorders and ocular conditions caused by haploinsufficiency.
Key content categories include treatment development timelines, partnership announcements with academic institutions, and financial performance reports. All materials maintain rigorous scientific accuracy while remaining accessible to both professional analysts and engaged public stakeholders.
Bookmark this page for direct access to Stoke Therapeutics' latest breakthroughs in RNA splicing modulation and protein restoration therapies. Regularly updated to reflect new developments in precision medicine innovation.
Stoke Therapeutics (NASDAQ: STOK) reported Q2 2024 financial results and provided business updates. Key highlights include:
1. FDA removed Partial Clinical Hold on zorevunersen for Dravet syndrome
2. Phase 3 registrational study plans update expected in H2 2024
3. Phase 1 study (OSPREY) of STK-002 for ADOA to begin this year
4. $282.0 million in cash and equivalents as of June 30, 2024
5. Q2 2024 revenue: $4.8 million; Net loss: $25.7 million ($0.46 per share)
6. R&D expenses: $21.1 million; G&A expenses: $13.0 million
The company continues to advance its RNA medicine pipeline, with zorevunersen showing promising results in reducing seizures and improving cognition in Dravet syndrome patients.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine, has announced the granting of stock options to three new employees as an inducement for their employment. The grants, effective July 15, 2024, include options to purchase a total of 122,900 shares of common stock at an exercise price of $14.58 per share, equal to the closing price on the grant date.
These options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. The options have a 10-year term and are subject to the company's 2023 Inducement Plan and individual stock option agreements.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company, announced the grant of stock options to purchase 10,400 shares of common stock to a new employee, effective June 17, 2024. This inducement follows Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $15.60 per share, aligning with the closing price of Stoke’s stock on the grant date. The options vest over four years, with 1/4th vesting after one year and the remaining shares vesting monthly over the next 36 months. These options have a 10-year term and are governed by the 2023 Inducement Plan and the relevant stock option agreement.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology firm focused on RNA-based medicines, will present at two major investor conferences in June 2024. The events include the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 4:00 p.m. ET and the TD Cowen Genetic Medicines & RNA Summit on June 20 at 10:00 a.m. ET. Live webcasts and replays of these events will be accessible on the company's investor relations website.
Stoke Therapeutics (Nasdaq: STOK) announced the granting of stock options as a material inducement for the employment of their new Chief Financial Officer, Thomas Leggett, and four other new employees. Effective May 15, 2024, Mr. Leggett received options to purchase 396,200 shares at $14.13 per share, while the other four employees received options to purchase a combined total of 65,000 shares at the same price. Each option will vest over four years, with 1/4th vesting on the one-year anniversary and the remainder vesting monthly over the next 36 months, contingent on continued employment. The options have a 10-year term and are governed by the 2023 Inducement Plan and corresponding agreements.
Stoke Therapeutics (STOK) reported positive data supporting the potential of STK-001 as a disease-modifying medicine for Dravet syndrome. The company plans a randomized, controlled study update in late 2024. Recent financial results revealed $178.6 million in cash, with $120.3 million added from a public offering.
Stoke Therapeutics, Inc. (Nasdaq: STOK) appoints Thomas Leggett as Chief Financial Officer, replacing Stephen Tulipano. Leggett, with over 20 years of experience in biotechnology and investment banking, will lead the financial strategy and operations, overseeing the company's growth and development.
FAQ
What is the current stock price of Stoke Therapeutics (STOK)?
What is the market cap of Stoke Therapeutics (STOK)?
